Page 1 of Clinical Trials for peritoneal cavity cancer, 471 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Not yet recruiting
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Last Updated: February 15, 2012
Condition(s): Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Primary Peritoneal Cavity Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Primary Peritoneal Cavity Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Epithelial Cancer; Stage IIC Primary Peritoneal Cavity Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Primary Peritoneal Cavity Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Primary Peritoneal Cavity Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Primary Peritoneal Cavity Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Primary Peritoneal Cavity Cancer
2
Completed
Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
Last Updated: April 23, 2011
Condition(s): Ovarian Cancer; Primary Peritoneal Cavity Cancer
3
Recruiting
Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Last Updated: October 28, 2010
Condition(s): Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
4
Completed
Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Last Updated: September 20, 2010
Condition(s): Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
5
Recruiting
VTX-2337 and Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Last Updated: May 19, 2012
Condition(s): Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
6
Not yet recruiting
Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
Last Updated: July 27, 2011
Condition(s): Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
7
Recruiting
Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)
Last Updated: January 25, 2011
Condition(s): Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
8
Recruiting
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
Last Updated: May 22, 2012
Condition(s): Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
9
Recruiting
Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Last Updated: August 5, 2011
Condition(s): Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
10
Recruiting
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Last Updated: May 1, 2012
Condition(s): Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
11
Active, not recruiting
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Last Updated: January 24, 2012
Condition(s): Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
12
Recruiting
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Last Updated: May 13, 2012
Condition(s): Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer
13
Suspended
Lenalidomide and Doxorubicin Hydrochloride Liposome in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Last Updated: August 22, 2011
Condition(s): Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
14
Terminated
Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
Last Updated: July 13, 2011
Condition(s): Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
15
Recruiting
Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Last Updated: September 20, 2011
Condition(s): Fallopian Tube Cancer; Peritoneal Cavity Cancer; Recurrent Ovarian Epithelial Cancer
16
Recruiting
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Last Updated: May 24, 2012
Condition(s): Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
17
Recruiting
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Last Updated: August 25, 2011
Condition(s): Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
18
Completed
FR901228 in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer
Last Updated: April 23, 2011
Condition(s): Ovarian Cancer; Primary Peritoneal Cavity Cancer
19
Recruiting
Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
Last Updated: May 25, 2012
Condition(s): Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
20
Recruiting
Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Last Updated: May 24, 2012
Condition(s): Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=peritoneal+cavity+cancer

Page 1 of Clinical Trials for peritoneal cavity cancer, 471 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About